Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8042544 | 0.81 | EPHX2 (0.54) | EPHX2ALDH1A1SIGMAR1EPHX1TAS1R3 | |
| SCHEMBL3071717 | 0.79 | EPHX2 (0.61) | EPHX2ALDH1A1SIGMAR1EPHX1RAB9A | |
| SCHEMBL3068813 | 0.79 | EPHX1 (0.76) | EPHX2ALDH1A1SIGMAR1EPHX1TAS1R3 | |
| SCHEMBL3065279 | 0.79 | EPHX2 (0.53) | EPHX2ALDH1A1SIGMAR1EPHX1RAB9A | |
| SCHEMBL4865320 | 0.78 | EPHX2 (0.51) | EPHX2ALDH1A1SIGMAR1EPHX1TAS1R3 | |
| SCHEMBL15655475 | 0.78 | EPHX2 (0.59) | EPHX2ALDH1A1SIGMAR1EPHX1TAS1R3 | |
| SCHEMBL26089624 | 0.78 | EPHX2 (0.59) | EPHX2ALDH1A1SIGMAR1EPHX1TAS1R3 | |
| SCHEMBL15655473 | 0.78 | EPHX2 (0.59) | EPHX2ALDH1A1SIGMAR1EPHX1TAS1R3 | |
| SCHEMBL4461499 | 0.78 | EPHX2 (0.59) | EPHX2ALDH1A1SIGMAR1EPHX1TAS1R3 | |
| SCHEMBL15655476 | 0.78 | EPHX2 (0.59) | EPHX2ALDH1A1SIGMAR1EPHX1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164495-B | Covalent targeting of E3 ligases | 加利福尼亚大学董事会 | 2025-04-22 | — | — | CN | disclosed |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | disclosed |
| US-12161648-B2 | Covalent targeting of E3 ligases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| EP-3863642-A1 | COVALENT TARGETING OF E3 LIGASES | The Regents of the University of California (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113164495-A | Covalent targeting of E3 ligase | 加利福尼亚大学董事会 | 2021-07-23 | — | — | CN | disclosed |
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12161648-B2 | Covalent targeting of E3 ligases | RNF114, RNF4, RNF168 | EPHX2 4228/4885ALDH1A1 2969/4885SIGMAR1 4393/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | EPHX2 4228/4885ALDH1A1 2969/4885SIGMAR1 4393/4885 |
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | EPHX2 3472/4885ALDH1A1 245/4885SIGMAR1 4281/4885 |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | STUB1, XIAP, RBX1 | EPHX2 2230/4885ALDH1A1 2485/4885SIGMAR1 4311/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | EPHX2 3391/4885ALDH1A1 281/4885SIGMAR1 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.